Geriatric nutritional risk index accurately predicts cardiovascular mortality in incident hemodialysis patients  by Takahashi, Hiroshi et al.
OG
m
H
T
K
T
a
b
c
d
e
f
a
A
R
R
A
A
K
G
C
H
A
B
I
n
M
t
T
T
y
0
hJournal of Cardiology 64 (2014) 32–36
Contents lists available at ScienceDirect
Journal of Cardiology
journa l homepage: www.e lsev ier .com/ locate / j j cc
riginal article
eriatric nutritional risk index accurately predicts cardiovascular
ortality in incident hemodialysis patients
iroshi Takahashi (BSc)a,b, Yasuhiko Ito (MD, PhD)c,d,∗, Hideki Ishii (MD, PhD)e,
oru Aoyama (MD, PhD)a, Daisuke Kamoi (MD, PhD)a, Hirotake Kasuga (MD, PhD) f,
aoru Yasuda (MD, PhD)d, Shoichi Maruyama (MD, PhD)d, Seiichi Matsuo (MD, PhD)d,
oyoaki Murohara (MD, PhD)e, Yukio Yuzawa (MD, PhD)b
Cardiovascular Center, Nagoya Kyoritsu Hospital, Nagoya, Japan
Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan
Department of Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Department of Nephrology, Nagoya Kyoritsu Hospital, Nagoya, Japan
r t i c l e i n f o
rticle history:
eceived 24 August 2013
eceived in revised form 21 October 2013
ccepted 29 October 2013
vailable online 22 December 2013
eywords:
NRI
ardiovascular mortality
emodialysis
lbumin
MI
a b s t r a c t
Background: Cardiovascular disease (CVD) is a leading cause of death in end-stage renal disease (ESRD)
patients. Protein-energy wasting (PEW) or malnutrition is common in this population, and is associated
with increasing risk of mortality. The geriatric nutritional risk index (GNRI) has been developed as a tool
to assess the nutritional risk, and is associated with mortality not only in elderly patients but also in
ESRD patients. However, whether the GNRI could predict the mortality due to CVD remains unclear in
this population. We investigated the prognostic value of GNRI at initiation of hemodialysis (HD) therapy
for CVD mortality in a large cohort of ESRD patients.
Methods: Serum albumin, body weight, and height for calculating GNRI were measured in 1568 ESRD
patients. Thereafter, the patients were divided into quartiles according to GNRI levels [quartile 1 (Q1):
<84.9; Q2: 85.0–91.1; Q3: 91.2–97.2; and Q4: >97.3], and were followed up for up to 10 years.
Results: GNRI levels independently correlated with serum C-reactive-protein levels (ˇ =−0.126,
p<0.0001). Rates of freedom from CVD mortality for 10 years were 57.9%, 73.3%, 80.8%, and 89.2% in
Q1, Q2, Q3, and Q4, respectively (p<0.0001). The GNRI was an independent predictor of CVD mortality
(hazard ratio 3.42, 95% conﬁdence interval 2.05–5.70, p<0.0001 for Q1 vs. Q4). C-index was also greater
in an established CVD risk model with GNRI (0.749) compared to that with albumin (0.730), body mass
index (0.732), and alone (0.710). Similar results were observed for all-cause mortality.
Conclusion: GNRI at initiation of HD therapy could predict CVD mortality with incremental value of the
predictability compared to serum albumin and body mass index in ESRD patients.
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End-stage renaldisease (ESRD)patientshavebeenwidely recog-
ized as a highest risk group for cardiovascular disease (CVD) [1,2].
ortality risk due to CVD in ESRD patients is 10–30 times higher
han that in the general population [1], making it a leading cause
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of death [3]. Thus, risk stratiﬁcation for CVD mortality is clinically
important for improving survival in such subjects.
Protein-energy wasting (PEW) is a state of decreased body pro-
tein mass and energy fuels [4] that is reportedly prevalent in ESRD
patients [5,6]. PEW also can result not only from a simply inad-
equate diet, but can also be induced by various factors, especially
inﬂammatory processes [4,7,8]. To assess PEW, serum albumin lev-
els and body mass index (BMI) have been commonly used, and
hypoalbuminemia [9–12] and reduced BMI [12–14] are reported
to be strongly associated with increased risk of CVD morbidity
and mortality in this population. Geriatric nutritional risk index
(GNRI), which is calculated from both serum albumin and the com-
ponents of BMI (height and body weight), was developed as a
simpliﬁed screening tool to assess the nutritional risk [15], and has
vier Ltd. All rights reserved.
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een associated with mortality not only in elderly patients in var-
ous health-care settings [16,17], but also in ESRD patients [18].
ecently, the GNRI was also reported to predict CVD events includ-
ng CVD mortality in patients with heart failure [19,20]. However,
hether the GNRI could predict mortality due to CVD, which is a
eading cause of death, remains unclear in ESRD patients. We ret-
ospectively investigated the predictive value of the GNRI for CVD
ortality in a large cohort of ESRD patients who had just began
emodialysis (HD) therapy.
ethods
tudy population
This study consisted of 1568 consecutive ESRD patients who
lectively began HD therapy in Nagoya Kyoritsu Hospital (Nagoya,
apan), Kaikokai Central Clinic (Nagoya, Japan), Meiko Kyoritsu
linic (Nagoya, Japan), Ama Kyoritsu Clinic (Yatomi, Japan) and
njou Kyoritsu Clinic (Anjou, Japan) between January 1998 and
ecember 2009. Patients with acute renal failure, active inﬂamma-
ory diseases, or malignancies at the initiation of HD therapy were
xcluded. Diabetes was deﬁned as a history or presence of diabetes
nd/or a fasting plasma glucose concentration >126mg/dl, glycosy-
ated hemoglobin (HbA1c) concentration >6.5%, or the presence of
iabetic retinopathy. Hypertension was deﬁned as systolic blood
ressure >160mmHg and/or diastolic blood pressure >90mmHg
efore dialysis session, or a history of anti-hypertensive treatment.
moking habit was deﬁned either as a current habit or as having
iscontinued cigarette use within 6 months prior to starting HD.
eriatric nutritional risk index
All clinical data were obtained from individual medical records.
ematocrit, albumin, creatinine, lipid proﬁles, and C-reactive pro-
ein (CRP) were measured using blood samples, which were taken
efore HD sessions after 2-day interval (Monday or Tuesday) at
weeks after initiation of HD therapy. Body mass index (BMI) was
alculated from height and body weight data at 2 weeks after ini-
iation of HD, because the state of overhydration in most patients
as controlled by this period [12]. Body weight was deﬁned as ‘dry
eight’, measured after each HD session.
TheGNRIwas calculated from individuallyobtained serumalbu-
in levels and body weight 2 weeks after initiation of HD therapy,
s follows [21]:
NRI = [14.89×albumin (g/dl)+
[
41.7×
(
body weight
ideal body weight
)]
ody weight/ideal body weight was set to 1 when the patient’s
odyweight exceeded the ideal bodyweight. The ideal bodyweight
n the present study was deﬁned as the value calculated from the
eight and a BMI of 22 [21], instead of the value calculated using
he Lorentz formula in the original GNRI equation. Thereafter, the
atients were divided into quartiles according to GNRI levels as
uartile 1 (Q1): GNRI <84.9, Q2: 85.0–91.1, Q3: 91.2–97.2, and Q4:
NRI >97.3.
ollow-up study
Follow-up was concluded in June 2010. The time point of entry
as deﬁned as the initiation of HD therapy. Primary endpoint was
VD death, including those due to heart failure, myocardial infarc-
ion, arrhythmia, sudden death, stroke, and other CVD-related
eaths. Secondary endpointwas all-causedeath.Data for endpoints
ere obtained from hospital charts and through telephone inter-
iews with patients, conducted by trained reviewers who wererdiology 64 (2014) 32–36 33
blinded to the protocol. In the present study, cases of unwitnessed
death were counted as cardiac death.
The studyprotocol and chart reviewsusedwere approvedby the
institutional ethics committeesof all hospitals, andwere conducted
in accordance with the Declaration of Helsinki.
Statistical analyses
Statistical analyses were performed using SAS 6.10 software
(SAS Institute, Cary, NC, USA). Variables with a normal distribution
are expressed asmean values± SD, and asymmetrically distributed
data are given as median and interquartile range (IQR). Differences
between the groups were evaluated by one-way analysis of vari-
ance (ANOVA) or Kruskal–Wallis test for continuous variables and
by chi-square test for categorical variables. To determine the fac-
tors that correlatedwithGNRI,multivariate regressionanalysiswas
used. Differences in event-free survival among the groups were
examined with the Kaplan–Meier method and compared using a
log-rank test. Hazard ratios (HR) and 95% conﬁdence intervals (CI)
were calculated for each factor by a Cox proportional hazards anal-
ysis. All baseline variables with p<0.05 by univariate analysis were
entered into a multivariate model to determine independent pre-
dictors for the endpoint.
To assess whether the accuracy of predicting mortality would
improve after the addition of GNRI into a baseline model with
established risk factors, including gender, age, diabetes, hyperten-
sion, dyslipidemia, smoking status, hematocrit, creatinine, calcium,
phosphate, and CRP, we calculated C-index, net reclassiﬁcation
improvement (NRI), and integrated discrimination improvement
(IDI). The C-index is deﬁned as the area under receiver-operating
characteristic (ROC) curvesbetween individualpredictiveprobabil-
ities formortality and incidence ofmortality, andwas compared for
the baselinemodel and enrichedmodels containing the established
risk factors plus BMI, serum albumin, and GNRI, respectively [22].
The NRI indicates relatively how many patients improve their pre-
dicted probabilities for mortality, while IDI represents the average
improvement in predicted probabilities for mortality after adding
variables into the baselinemodel [23]. Differenceswere considered
statistically signiﬁcant at p<0.05.
Results
Clinical characteristics
Characteristics of the study population are shown in Table 1.
These characteristics were similar to those of average HD patients
in Japan [2]. On multivariate regression analysis, GNRI levels were
independently correlated with male gender (ˇ =−0.060, p=0.045),
age (ˇ =−0.155, p<0.0001), hematocrit (ˇ =0.128, p<0.0001),
creatinine (ˇ =0.287, p<0.0001), and serum CRP (ˇ =−0.126,
p<0.0001) (Table 2).
Prognostic value of geriatric nutritional risk index
During the follow-upperiod (mean63±42months), 93patients
moved out to other institutes and 19 underwent renal transplanta-
tion, and they were censored at the point of moving out. A total of
363 patients (23.1%) died, including 180 deaths (11.5%) due to CVD
(56 heart failure, 26 myocardial infarction, 15 fatal arrhythmia, 23
sudden death, 48 stroke, 4 aortic aneurysm, and 8 others). At the
10-year follow-up, Kaplan–Meier survival rates for CVD mortality
were 57.9%, 73.3%, 80.8%, and 89.2% in Q1, Q2, Q3, and Q4, respec-
tively (p<0.0001) (Fig. 1). After adjustment for other confounders,
GNRI was an independent predictor of CVD mortality [hazard ratio
(HR) 1.72, 95% conﬁdence interval (CI) 1.00–2.96, p=0.049 for Q3
vs. Q4, HR 1.99, 95% CI 1.16–3.41, p=0.012 for Q2 vs. Q4, and HR
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Table 1
Baseline patient characteristics.
All patients
(n=1568)
Quartile 1 <84.9
(n=396)
Quartile 2 ≥84.9
to <91.1 (n=388)
Quartile 3 ≥91.1
to <97.3 (n=392)
Quartile 4 ≥97.3
(n=392)
p-Value
Male (%) 66.9 68.2 62.0 68.6 68.9 0.12
Age (years) 64±13 68±12 65±12 63±12 58±14 <0.0001
Diabetes (%) 52.0 52.0 56.2 52.3 47.7 0.14
Hypertension (%) 74.1 72.0 72.4 76.3 75.8 0.41
Smoking (%) 21.8 21.2 19.4 19.9 26.5 0.12
Body mass index (kg/m2) 21.1±3.4 18.6±2.5 20.1±2.1 21.4±2.2 24.5±3.4 <0.0001
Hematocrit (%) 29.7±4.3 28.5±4.3 29.6±4.3 30.2±4.1 30.6±4.4 <0.0001
Albumin (g/dl) 3.4±0.5 2.9±0.4 3.4±0.3 3.6±0.3 3.8±0.4 <0.0001
Creatinine (mg/dl) 7.8±3.2 6.6±2.1 7.2±2.2 8.2±2.5 9.3±4.6 <0.0001
Total cholesterol (mg/dl) 164±38 163±40 165±37 165±38 162±35 0.68
LDL-cholesterol (mg/dl) 91±32 90±33 92±32 92±31 90±29 0.67
HDL-cholesterol (mg/dl) 44±14 45±14 46±15 43±12 43±16 0.32
C-reactive protein (mg/l) 1.8 (0.8–5.7) 2.6 (1.0–8.6) 1.7 (0.7–5.8) 1.5 (0.7–4.5) 1.4 (0.6–3.7) <0.0001
LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Table 2
Relationship between geriatric nutritional risk index and baseline variables by mul-
tivariate regression analysis.
ˇ p-Value
Male −0.060 0.045
Age −0.155 <0.0001
Diabetes 0.022 0.46
Hypertension 0.038 0.18
Smoking −0.035 0.26
Hematocrit 0.128 <0.0001
Creatinine 0.287 <0.0001
Total cholesterol −0.023 0.82
LDL-cholesterol 0.007 0.80
HDL-cholesterol −0.061 0.24
Log CRP −0.126 <0.0001
L
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HDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive
rotein.
.42, 95% CI 2.05–5.70, p<0.0001 for Q1 vs. Q4] (Table 3). Regarding
odel discrimination, C-index for CVD mortality was greater in
he baseline model plus BMI (0.732, p=0.036) and plus albumin
0.730,p=0.0036) as compared to the baselinemodel alone (0.710),
nd was much greater in the model plus GNRI (0.749, p=0.0003),
ith a statistically signiﬁcant difference between the model plus
MI (p=0.034) and plus albumin (p=0.012) (Table 4). The NRI and
DI for CVD mortality also signiﬁcantly increased after adding BMI
0.303 and 0.0098), albumin (0.223 and 0.0046), and GNRI (0.385
nd0.0148) into the baselinemodel. Furthermore, both theNRI and
DI signiﬁcantly increased in the model plus GNRI, even compared
able 3
rognostic value of geriatric nutritional risk index for cardiovascular mortality on Cox an
Non-adjusted
HR (95%CI) p-
GNRI (vs. Q4) <0
Q3 1.91 (1.09–3.34) 0
Q2 2.55 (1.47–4.42) 0
Q1 4.41 (2.63–7.39) <0
Male 1.38 (0.99–1.91) 0
Age 1.05 (1.04–1.07) <0
Diabetes 1.76 (1.30–2.38) 0
Hypertension 1.41 (1.01–1.95) 0
Smoking 1.30 (0.52–1.84) 0
Hematocrit 0.98 (0.95–1.01) 0
Creatinine 0.82 (0.77–0.88) <0
Total cholesterol 0.99 (0.99–1.00) 0
LDL-cholesterol 1.00 (1.00–1.01) 0
HDL-cholesterol 0.97 (0.92–1.01) 0
C-reactive protein 1.22 (1.13–1.34) <0
R, hazard ratio; CI, conﬁdence interval; Q, quartile; GNRI, geriatric nutritional risk index
* p for trend. Multivariate model includes all variables at baseline with p<0.05 by univFig. 1. Kaplan–Meier survival curves for cardiovascular mortality among quartiles
(Q) according to geriatric nutritional risk index levels at initiation of hemodialysis
therapy.
to the model plus BMI (p=0.046 and p=0.027) and plus albumin
(p=0.0002 and p<0.0001), respectively (Table 4). Similar results
were observed for all-causemortality (Supplementary Fig. 1, Tables
1 and 2) as well as the previous report [18].Discussion
In the present study, we clearly demonstrated that GNRI, orig-
inally reported as a tool to assess nutritional status in the elderly,
alysis.
Adjusted
Value HR (95%CI) p-Value
.0001* <0.0001*
.0046 1.72 (1.00–2.96) 0.049
.0002 1.99 (1.16–3.41) 0.012
.0001 3.42 (2.05–5.70) <0.0001
.054
.0001 1.04 (1.03–1.06) <0.0001
.0002 2.08 (1.48–2.92) <0.0001
.042 1.24 (0.85–1.80) 0.27
.15
.17
.0001 0.95 (0.87–1.03) 0.18
.36
.38
.14
.0001 1.09 (1.02–1.16) 0.0075
; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
ariate analysis.
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Table 4
Discrimination of each predictive model for cardiovascular mortality using C-index, net reclassiﬁcation improvement and integrated discrimination improvement.
Predictive models C-index p-Value NRI p-Value IDI p-Value
Established risk factors 0.710 (0.670–0.750) Reference Reference Reference
+BMI 0.732 (0.694–0.769) 0.036 0.303 0.0002 0.0098 <0.0001
+Albumin 0.730 (0.692–0.769) 0.0036 0.223 0.0047 0.0046 0.010
+GNRI 0.749 (0.714–0.785) 0.0003 0.385 <0.0001 0.0148 <0.0001
+GNRI vs. +BMI 0.018 (0.001–0.034)a 0.034 0.144 0.046 0.0050 0.027
+ GNRI vs. +albumin 0.019 (0.004–0.034)a 0.012 0.309 0.0002 0.0102 <0.0001
Established risk factors included gender, age, diabetes, hypertension, smoking status, hematocrit, creatinine, cholesterols, and C-reactive protein levels.
NRI, net reclassiﬁcation improvement; IDI, integrated discrimination improvement; BMI, body mass index; GNRI, geriatric nutritional risk index.
a Differences between two models.
Table 5
Prevalence of nutritional risk according to geriatric nutritional risk index levels in various populations.
n Age Nutritional risk (%)
Severe/moderate <92 Low ≥92 to <98 None ≥98
Rehabilitation-care [15] 2474 83 ± 2 43.6 29.4 27.0
Home-care [16] 241 80 ± 8 20.7 36.1 43.2
Long-term care [17] 358 85 ± 8 37.4 34.9 27.3
± 13
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SRD, end-stage renal disease; HD, hemodialysis.
ould not only predict CVD mortality, but also improve the pre-
ictive accuracy of mortality compared to other predictive models
ncluding albumin or BMI, with increasing C-statistics, NRI and IDI,
n ESRD patients at the initiation of HD therapy.
Since Stenvinkel et al. reported that malnutrition is closely
inked with elevated inﬂammatory cytokines and carotid intima-
edia atherosclerosis in ESRD patients [8], so-called malnutrition,
nﬂammation, and atherosclerosis (MIA) syndrome was consid-
red to be an important issue for clinical management in this
opulation. For example, Joki et al. [11] found the association of
ypoalbuminemia with advanced coronary artery disease at initi-
tion of HD therapy, and Kaysen et al. [24] also demonstrated that
nﬂammatory responses, such as elevated CRP and interleukin-6,
educe albumin synthesis resulting in hypoalbuminemia. Recently,
e reported that both hypoalbuminemia and elevated CRP levels
ould predict major adverse cardiovascular events after endovas-
ular therapy in chronic HD patients with peripheral artery disease
25]. The PEW is the newly integrated terminology developed from
he concept of theMIA syndrome, deﬁnedby the expert panel of the
nternational Society of Renal Nutrition and Metabolism (ISRNM)
4]. In this regard, our present study conﬁrmed that declining GNRI
s closely associated with elevated CRP, thus, the GNRI is suggested
o be a useful diagnostic tool for the PEW as a predictor of CVD
ortality in ESRD patients.
Furthermore, an important ﬁnding of the present study is that
he CVD mortality-predicting model using GNRI is superior to that
sing albumin and BMI alone, with increasing C-statistics, NRI, and
DI as indices of improvement of the predictive ability. Hypoalbu-
inemia and low BMI are deﬁned as important criteria to diagnose
he PEW from the expert panel of the ISRNM [4], because both of
hemhave strong and consistent outcome-predictability ofmortal-
ty [9–14], even though the former is often associated with severe
isease states, and the latter is inﬂuenced by fat mass or the state
f overhydration [4]. However, the PEW is a complex syndrome
onsisting of multiple factors. In this regard, because the GNRI is
n integrated expression, consisting of albumin and components
f BMI (height and body weight), and is regarded as a multiple
odel itself, it might be practically superior when screening the
utritional risk in this population.
Various studies using different criteria have reported that the
revalence of PEW was approximately 18–75% in ESRD patients
4–7]. In the present study, crudely based on the classiﬁcation of53.4 23.3 23.3
nutritional risk according to GNRI by Bouillanne et al. [15], at least
half of ESRD patients suffer from severe/moderate nutritional risk
(GNRI <92) at the start of HD therapy. Furthermore, this preva-
lence rate was much higher than in various elderly populations
(20.7–43.6%) [15–17], even though ESRD patients were younger
than these elderly people (Table 5). This high prevalence should
be borne in mind to identify the patients at CVD mortality risk.
Whether the nutritional risk improves with HD therapy or not also
needs to be investigated.
There are several limitations to the present study. First, all the
study subjects were Japanese, who reportedly have a better prog-
nosis as compared to patients in the USA and Europe; further,
subclinical atherosclerosis, coronary disease mortality and risk of
coronary calciﬁcation are lower in Japanesepeople [26]. Second,we
only analyzed the predictive value of GNRI at the start of HD ther-
apy, and did not analyze the impact on mortality of improvements
in this value after starting HD therapy.
In conclusion, GNRI values at the start of HD therapy could not
only predict CVD mortality, but also improve the accuracy of CVD
mortality prediction in ESRD patients. This simple screening tool,
using common variables that can be easily obtained in daily clinical
practice, might be clinically useful for the assessment of PEW as a
CVD mortality risk in this population.
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